Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 14Gynecologic 12Thoracic 6Breast 6Genitourinary 3Lymphoid 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1

Conditions

Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mass Screening × Plasma cell × Clear all
NCT05844033 2026-05-19

Biomarker for Infection Risk in CLL and MM

Massachusetts General Hospital

Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡